Autoimmune Cytopenias

In this review, researchers from multiple centers in France describe current management of ITP and highlight research that has already advanced treatment or may inform future therapies, including inhibition of phagocytosis (including inhibition of Syk and BTK); modulation of phagocytosis; inhibition of FcRn (neonatal receptor of the Fc portion of immunoglobulins); agents targeting B cells, T cells, and plasma cells; inhibition of the classical complement pathway and platelet desialylation; and enhancement of thrombopoiesis.